Quintrio
Home

ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS

CeriBell, Inc. Common Stock

CBLL

CeriBell Inc is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Its products are Point-of-Care EEG, Clarity, and EEG Portal.

Last trade $26.64
Day change +$0.22 (+0.83%)
Day range $26.37 – $29.19
Volume 147,396
Market cap $1.03B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.03B
Price / earnings
—
Price / book
8.73×
Price / sales
9.44×
EV / sales
9.24×
EV / EBITDA
-13.41×

Profitability

Earnings per share
-$1.90
Return on assets
-47.25%
Return on equity
-62.86%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.17×
Current ratio
8.18×
Quick ratio
7.79×
Cash ratio
2.33×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$57.19M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CBLL, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$29.34M$28.1M$26.49M$24.78M$22.59M$21.2M$20.49M$18.53M
Cost of revenue$3M$2.16M$3.37M$3.14M$2.65M$2.52M$2.48M$2.3M
Gross profit$26.34M$25.94M$23.12M$21.64M$19.94M$18.68M$18.01M$16.24M
Selling, general and administrative$39.49M$39.17M$37.71M$31.18M$29.61M$28.78M$27.97M$25.21M
Research and development$7.4M$6.75M$6.16M$5.06M$4.98M$4.85M$4.25M$3.91M
Total operating expenses$46.89M$45.92M$43.87M$36.24M$34.59M$33.63M$32.21M$29.12M
Operating income-$20.55M-$19.98M-$20.75M-$14.6M-$14.65M-$14.95M-$14.21M-$12.88M
Interest expense-$267K-$438K-$434K-$462K-$480K-$477K-$471K-$499K
Income before taxes-$21.35M-$19.27M-$19.74M-$13.53M-$13.47M-$13.64M-$12.78M-$12.58M
Income taxes$0$0$0$0$0$0$0$0
Net income-$21.35M-$19.27M-$19.74M-$13.53M-$13.47M-$13.64M-$12.78M-$12.58M
Net income attributable to common shareholders-$21.35M-$19.27M-$19.74M-$13.53M-$13.47M-$13.64M-$12.78M-$12.58M
EBITDA-$20.3M-$19.74M-$20.51M-$14.31M-$14.26M-$14.63M-$13.87M-$12.52M
Basic earnings per share-$0.55-$0.51-$0.52-$0.36-$0.37-$0.38-$0.36-$0.40
Diluted earnings per share-$0.55-$0.51-$0.52-$0.36-$0.37-$0.38-$0.36-$0.40

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

CeriBell, Inc. (CBLL) Reports Q3 Loss, Tops Revenue Estimates

CeriBell, Inc. (CBLL) reported a quarterly loss of $0.48 per share, beating consensus estimates of $0.50 loss, with revenues of $29.34 million exceeding expectations by 0.70%. However, losses widened year-over-year from $0.37 to $0.48 per share. The stock has gained 22.9% year-to-date but carries a Zacks Rank #3 (Hold) rating, with the Medical-Products industry ranking in the bottom 35% of sectors.

Zacks Investment Research

Compared to Estimates, CeriBell, Inc. (CBLL) Q3 Earnings: A Look at Key Metrics

CeriBell, Inc. reported Q3 2026 revenue of $29.34 million, beating estimates by 0.7% with 29.9% year-over-year growth. The company posted an EPS of -$0.48, outperforming the consensus estimate of -$0.50 by 4%. Key metrics showed Total Active Accounts at $747 million and strong growth in EEG headband revenue at $22.24 million (+30.6% YoY). The stock holds a Zacks Rank #3 (Hold) rating and has returned 8.5% over the past month.

GlobeNewswire Inc.

Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O’Keefe

Ceribell announced the appointment of Thomas West and Sharon O'Keefe to its Board of Directors. West, former CEO of Nalu Medical (acquired by Boston Scientific for $600M) and Intersect ENT (acquired by Medtronic for $1.1B), and O'Keefe, former President of University of Chicago Medical Center, bring significant commercial and health-system leadership experience. The appointments support Ceribell's expansion as its point-of-care brain monitoring platform is now deployed in over 680 U.S. hospitals.

GlobeNewswire Inc.

Medtech Leader Erica Rogers Joins Ceribell Board of Directors

Medical technology company Ceribell announced the appointment of Erica Rogers to its Board of Directors, bringing over three decades of healthcare leadership experience to help expand nationwide access to their point-of-care EEG system.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.